0
Startups & Venture·November 17, 2026·1 min read

Neuralink co-founder Max Hodak's Science Corp, which offers a retinal implant for age-related macular degeneration, raised $400M at a $3.5B valuation

Share

$400M at a $3.5B valuation for a retinal implant company shows capital is ready to fund invasive neurotech that delivers concrete clinical outcomes, not just research. Healthcare operators should expect patient expectations — and regulatory scrutiny — around brain-adjacent devices to rise quickly as these move from trials into practice.